- Advertisement -

The share price of antimicrobial treatmentsdeveloper Destiny Pharma (LON: DEST) has done badly since the shares were recommended back in June. The key to the progress of the share price is likely to be positive news about the phase 3 trials for X-73, which prevents post-surgical infections, and c.diff prevention treatment NTCD-M3.

The phase 2b study results for XF-73 nasal gel were better than many expected and the prospects for both potential treatments are good. A phase 3 study design proposal has been submitted to the authorities and the details could be finalised before the end of the year.

Cash is always the key point in any results and the Destiny Pharma interims were no different. There was net cash of £7.1m at the end of June, down from £9.7m at the end of 2020, and this cou...